Alexander D. Sherry

965 total citations
73 papers, 379 citations indexed

About

Alexander D. Sherry is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Alexander D. Sherry has authored 73 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 18 papers in Epidemiology. Recurrent topics in Alexander D. Sherry's work include Statistical Methods in Clinical Trials (15 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Meningioma and schwannoma management (12 papers). Alexander D. Sherry is often cited by papers focused on Statistical Methods in Clinical Trials (15 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Meningioma and schwannoma management (12 papers). Alexander D. Sherry collaborates with scholars based in United States, United Kingdom and Israel. Alexander D. Sherry's co-authors include Neil B. Newman, Evan C. Osmundson, Mohamed H. Khattab, Anthony J. Cmelak, Ethan B. Ludmir, Albert Attia, Tim Hodgson, A. Bapsi Chakravarthy, Elizabeth Molyneux and Stephen Porter and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Alexander D. Sherry

64 papers receiving 373 citations

Peers

Countries citing papers authored by Alexander D. Sherry

Since Specialization

Citations

This map shows the geographic impact of Alexander D. Sherry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander D. Sherry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander D. Sherry more than expected).

Fields of papers citing papers by Alexander D. Sherry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander D. Sherry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander D. Sherry. The network helps show where Alexander D. Sherry may publish in the future.

Co-authorship network of co-authors of Alexander D. Sherry

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander D. Sherry. A scholar is included among the top collaborators of Alexander D. Sherry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander D. Sherry. Alexander D. Sherry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Evidence on Particle Radiation, DNA Damage Response Inhibitors, and Immunotherapy for Mismatch Repair-Proficient Rectal Cancer 2026 ·Cancers ·(unknown), (unknown), Jake A. Kloeber, (unknown), (unknown), Michael G. Haddock, Yasamin Sharifzadeh, Alexander D. Sherry, (unknown), (unknown), Kenneth W. Merrell, Robert W. Mutter, Zhenkun Lou, (unknown)	0
2	Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma 2025 ·Seminars in Radiation Oncology ·Alexander D. Sherry, (unknown), Ryan M. Carr, Mark J. Truty, Krishan R. Jethwa	0
3	World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration. 2025 ·Journal of Clinical Oncology ·Chad Tang, Alexander D. Sherry, Hyunsoo Hwang, Giulio Francolini, (unknown), Phuoc T. Tran, Paul G. Corn, Ana M. Aparicio, Gabriele Simontacchi, Ana P. Kiess, Jarey H. Wang, Valérie Fonteyne, Renée Bultijnck, Robert Olson, Stephen Harrow, Ethan B. Ludmir, Pierre Blanchard, (unknown), David A. Palma, David E. Ost	9
4	Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives. 2025 ·Journal of Clinical Oncology ·Alexander D. Sherry, Cara Haymaker, Bryan Fellman, Tharakeswara Bathala, (unknown), Suyu Liu, Stephen G. Chun, (unknown), (unknown), (unknown), Matthew P. Deek, Ana M. Aparicio, Amado J. Zurita, Patrick G. Pilié, Bilal A. Siddiqui, Sumit K. Subudhi, Alexandre Reuben, Paul G. Corn, Phuoc T. Tran, Chad Tang	1
5	Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses 2024 ·JCO Clinical Cancer Informatics ·Alexander D. Sherry, (unknown), Zachary R. McCaw, Joseph Abi Jaoude, Timothy A. Lin, Ramez Kouzy, (unknown), (unknown), (unknown), Pavlos Msaouel, Ethan B. Ludmir	4
6	Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials 2024 ·Cancer Research Communications ·(unknown), Alexander D. Sherry, Marcus A. Florez, Ramez Kouzy, Joseph Abi Jaoude, Timothy A. Lin, (unknown), (unknown), (unknown), Roshal R. Patel, Fumiko Chino, (unknown), Christine M. Parseghian, Michael J. Overman, Bruce D. Minsky, Charles R. Thomas, Chad Tang, Pavlos Msaouel, Ethan B. Ludmir	1
7	Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation 2024 ·Clinical Cancer Research ·Timothy A. Lin, Zachary R. McCaw, (unknown), (unknown), Joseph Abi Jaoude, Roshal R. Patel, Ramez Kouzy, Molly B. El Alam, Alexander D. Sherry, Sonal S. Noticewala, Clifton D. Fuller, Charles R. Thomas, Ryan Sun, J. Jack Lee, Ruitao Lin, Ying Yuan, Yu Shyr, Tomer Meirson, Ethan B. Ludmir	4
8	Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020 2024 ·JAMA Network Open ·Alexander D. Sherry, Andrew W. Hahn, Zachary R. McCaw, Joseph Abi Jaoude, Ramez Kouzy, Timothy A. Lin, Bruce D. Minsky, Clifton D. Fuller, Tomer Meirson, Pavlos Msaouel, Ethan B. Ludmir	3
9	Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Alexander D. Sherry, Timothy A. Lin, Zachary R. McCaw, (unknown), Ramez Kouzy, Joseph Abi Jaoude, (unknown), (unknown), (unknown), Clifton D. Fuller, Charles R. Thomas, Eugene J. Koay, Chad Tang, Pavlos Msaouel, Ethan B. Ludmir	0
10	Peripheral T-Cell Priming and Micrometastatic Disease Control with Metastasis-Directed Therapy: Multidimensional Immunogenomic Profiling of Oligometastatic Prostate Cancer in the EXTEND Trial 2023 ·International Journal of Radiation OncologyBiologyPhysics ·Alexander D. Sherry, Cara Haymaker, Tharakeswara Bathala, Xian Lu, (unknown), Enrica Marmonti, (unknown), (unknown), Bryan Fellman, (unknown), (unknown), Stephen G. Chun, Ana M. Aparicio, (unknown), (unknown), Daniel R. Gomez, Alexandre Reuben, Ignacio I. Wistuba, Paul G. Corn, Chad Tang	1
11	Prevalence, trends, and characteristics of trials investigating local therapy in contemporary phase 3 clinical cancer research 2023 ·Cancer ·Alexander D. Sherry, Kelsey L. Corrigan, Ramez Kouzy, Joseph Abi Jaoude, (unknown), Roshal R. Patel, Douglas J. Totten, Neil B. Newman, Prajnan Das, Cullen M. Taniguchi, Bruce D. Minsky, Rebecca A. Snyder, Clifton D. Fuller, Ethan B. Ludmir	9
12	Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy 2023 ·European Journal of Cancer ·Alexander D. Sherry, Pavlos Msaouel, Zachary R. McCaw, Joseph Abi Jaoude, Eric J. Hsu, Ramez Kouzy, Roshal R. Patel, (unknown), Timothy A. Lin, Cullen M. Taniguchi, Claus Rödel, Emmanouil Fokas, Chad Tang, Clifton D. Fuller, Bruce D. Minsky, Tomer Meirson, Ryan Sun, Ethan B. Ludmir	6
13	Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer 2020 ·Journal of Thoracic Disease ·Neil B. Newman, (unknown), Alexander D. Sherry, Evan C. Osmundson	16
14	Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity 2020 ·Clinical Breast Cancer ·Alexander D. Sherry, Ingrid A. Mayer, D.N. Ayala-Peacock, Vandana G. Abramson, Brent N. Rexer, A. Bapsi Chakravarthy	13
15	Outcomes of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for refractory Cushing’s disease 2019 ·Pituitary ·Alexander D. Sherry, Mohamed H. Khattab, (unknown), Patrick D. Kelly, (unknown), (unknown), Andrea L. Utz, Lola B. Chambless, Anthony J. Cmelak, Albert Attia	7
16	Diffuse Primary Cutaneous Anaplastic Large Cell Lymphoma Treated by Rotational Total Skin Electron Beam Radiotherapy with Custom Shielding: Case Report 2019 ·Journal of medical imaging and radiation sciences ·Alexander D. Sherry, G Ding, Austin N. Kirschner	1
17	The Sooner the Better: High-Value Care Education in Medical School 2019 ·Academic Medicine ·(unknown), (unknown), Sanjana Salwi, (unknown), Alexander D. Sherry	7
18	Fundamental Curriculum Change with 1-Year Pre-Clerkship Phase and Effect on Stress Associated with Residency Specialty Selection 2019 ·Medical Science Educator ·(unknown), Alexander D. Sherry, (unknown), (unknown), Andrew W. Kuhn, Amy E. Fleming	7
19	Dose-Dependent Association of Vertebral Body irradiation and Lymphopenia During Chemoradiation for Esophageal Cancer 2018 ·International Journal of Radiation OncologyBiologyPhysics ·Neil B. Newman, Alexander D. Sherry, (unknown), Evan C. Osmundson	4
20	Antibiotic‐treated infections in intensive care patients in the UK 2004 ·Anaesthesia ·B. H. Cuthbertson, Marlus M. Thompson, Alexander D. Sherry, (unknown), (unknown), (unknown)	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact